Scarica l'app Stockscreener
0.73
0.82%
-0.006
Pre-mercato:
1.03
0.30
+41.10%
Glucotrack Inc Borsa (GCTK) Ultime notizie
GlucoTrack Executes Debt-for-Equity Exchange and Investor Update - The Globe and Mail
Peer-Reviewed Study in Journal of Diabetes Research Verifies Glucotrack’s Long‑Term Continuous Blood Glucose Monitoring Technology - citybiz
[EFFECT] Glucotrack, Inc. SEC Filing - Stock Titan
Glucotrack (NASDAQ: GCTK) swaps $988K debt for 1.3M new shares - Stock Titan
GlucoTrack Reports Strong Preclinical Data for Implantable CBGM - TipRanks
Peer-reviewed CBGM data back Glucotrack (NASDAQ: GCTK) IDE plans - Stock Titan
Glucotrack publishes 240-day glucose monitor study results - Investing.com
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology - The Manila Times
An implantable glucose monitor held accuracy for 240 days in animal study - Stock Titan
Glucotrack, Inc. (NASDAQ: GCTK) registers 20.06M shares tied to $20M financing - Stock Titan
GCTK Stock Chops Higher As GlucoTrack Marks Key CGM Milestones - StocksToTrade
GCTK Stock Pops As GlucoTrack Marks Key CGM Milestones - timothysykes.com
GlucoTrack stock gains as data backs FDA filing plans for glucose monitoring tech - MSN
GCTK stock is soaring pre-market today — what is fueling the surge? - MSN
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
GlucoTrack Stock Short Interest Falls to 73.9% - Quiver Quantitative
GlucoTrack files to sell 20.06M shares of common stock by selling shareholders - MSN
GCTK GlucoTrack lays out new commercial growth plans in its latest quarterly earnings release for non-invasive glucose monitors.Dividend Report - Cổng thông tin điện tử tỉnh Tây Ninh
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant - Yahoo Finance
GlucoTrack announces publication of peer-reviewed article on glucose sensors - TipRanks
New Peer-Reviewed Study Supports Glucotrack’s Long-Duration Implantable Continuous Blood Glucose Monitoring Technology - citybiz
Glucotrack publishes peer-reviewed study on glucose sensor stability - Investing.com
Glucotrack publishes peer-reviewed study on glucose sensor stability By Investing.com - Investing.com Canada
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology - marketscreener.com
One-year lab test backs Glucotrack implantable glucose monitor - Stock Titan
GlucoTrack (GCTK) Stock Investment Today (Volatility Increases) 2026-04-20Turnaround Stocks - Cổng thông tin điện tử tỉnh Lào Cai
GCTK | GlucoTrack, Inc. Common Stock Insider Trading - Quiver Quantitative
GlucoTrack (GCTK) Stock Volume Drop (Smart Money Active) 2026-04-18Shared Buy Zones - Newser
Should You Hold GlucoTrack (GCTK) Stock? (Technical Weakness) 2026-04-16Momentum Signals - Xã Vĩnh Công
GlucoTrack Executes Debt-for-Equity Exchange to Reduce Obligations - The Globe and Mail
Glucotrack exchanges $600,000 note for 895,000 shares with investor By Investing.com - Investing.com
Glucotrack Swaps $600,000 Note Portion for 895,000 Shares Under Exchange Agreement - TradingView
Glucotrack (NASDAQ: GCTK) swaps $600K debt for 895,000 shares - Stock Titan
Technical Analysis: Is GlucoTrack Inc impacted by rising ratesProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
$Glucotrack (GCTK.US)$ thanks market - Moomoo
RSI Check: Will GlucoTrack Inc benefit from geopolitical trends2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer
Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart
GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - TradingView — Track All Markets
Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan
Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative
Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan
Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget
GCTK PE Ratio & Valuation, Is GCTK Overvalued - Intellectia AI
GlucoTrack, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
0.78%
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):